Radiation after liver cancer surgery with narrow margins
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding a type of radiation (SIB radiotherapy) after liver cancer surgery can improve outcomes for patients whose tumors were removed with very narrow clear margins (less than 1 cm). It may help reduce the chance of cancer coming back in the remaining liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cancer (HCC) and had surgery to remove it.
- The pathologist found that the clear margin around your tumor was less than 1 cm.
- You are at least 18 years old.
- You have recovered well from surgery and are able to care for yourself (ECOG score 0 or 1).
- Your liver function is good (Child-Pugh score A5-A6).
- You have no cancer spread to other parts of the body (no distant metastases).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments after liver cancer surgery to see which better prevents the cancer from coming back. You may be eligible if your surgery had a narrow margin and you have certain risk factors, like a tumor over 5 cm or high AFP levels.
This trial tests whether combining chemotherapy with radiation after surgery can help prevent the return of intrahepatic cholangiocarcinoma, a type of bile duct cancer. It is for people whose surgery showed a narrow margin or cancer in nearby lymph nodes.
This trial is testing whether giving focused radiation therapy (SBRT) after liver surgery helps lower the chance of cancer coming back. It is for people whose surgery left a very small safety margin around the tumor.
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
This trial tests a targeted radiation treatment (SIRT) for people with liver cancer that is still confined to one side of the liver and has not been treated before. The goal is to see if SIRT can shrink the tumor enough to make surgical removal possible.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) for liver cancer that can be removed with surgery. The goal is to see if this combination can shrink tumors before surgery and help prevent the cancer from coming back.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.